Clinical trials
Completed trials in Spain
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
14,491 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 42 |
| 2001 | 84 |
| 2002 | 103 |
| 2003 | 164 |
| 2004 | 227 |
| 2005 | 280 |
| 2006 | 357 |
| 2007 | 378 |
| 2008 | 470 |
| 2009 | 524 |
| 2010 | 534 |
| 2011 | 639 |
| 2012 | 684 |
| 2013 | 675 |
| 2014 | 737 |
| 2015 | 759 |
| 2016 | 783 |
| 2017 | 881 |
| 2018 | 947 |
| 2019 | 963 |
| 2020 | 949 |
| 2021 | 949 |
| 2022 | 823 |
| 2023 | 637 |
| 2024 | 488 |
| 2025 | 253 |
| 2026 | 60 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 14,491 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Novartis Pharmaceuticals | 468 |
| Hoffmann-La Roche | 459 |
| AstraZeneca | 318 |
| Pfizer | 314 |
| GlaxoSmithKline | 308 |
| Eli Lilly and Company | 237 |
| Bayer | 233 |
| Boehringer Ingelheim | 232 |
| Bristol-Myers Squibb | 232 |
| Sanofi | 223 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Breast Neoplasms | 448 |
| Neoplasms | 354 |
| Diabetes Mellitus, Type 2 | 322 |
| Carcinoma, Non-Small-Cell Lung | 321 |
| COVID-19 | 235 |
| Colorectal Neoplasms | 209 |
| Pain | 209 |
| Pulmonary Disease, Chronic Obstructive | 203 |
| HIV Infections | 201 |
| Obesity | 196 |
Trials
Showing 26 to 50 of 14,491. Each trial links to its page on Pharma Observatory.
14,391 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.